Dipharma S.A. is a Swiss specialty pharmaceutical company, developing high quality, improved, medicines for rare diseases. Dipharma S.A. is part of a third-generation group of family-owned companies that have grown to a global presence.
With a portfolio of generic orphan products for the treatment of Phenylketonuria, Gaucher Disease, Hereditary Tyrosinemia Type 1, Urea Cycle Disorders and others, Dipharma S.A. provides improved solutions for patients affected by inborn metabolic diseases at an affordable cost and with a global reach.
Piazza Col. C. Bernasconi 5
|T.: +41 91 60 11 700|
|Persona di contatto: Marc-Olivier Geinoz|
Attività principali Licensing-In ● Licensing-Out ● Co-development ○ Trading ●
Fasi di sviluppo Registration ● Market ● Generic Plus (505B2) ○ Generic ● Life cycle management ●
Aree terapeutiche Metabolism ●
Mercati CH ○ EU Top 5 ● Rest of Europe ○ USA and Canada ● LATAM ○ MENA ○ BRICS ○ ASEAN ○ Africa ○ Australia ○ Brazil ○ China ○ Japan ○ Korea ○